Blog
RSS FeedPosted by Michael Wonder on 06 Feb 2024
Updates on NICE and SMC collaboration on MTA for cystic fibrosis
1 February 2024 - On 19 December 2023, we advised that NICE would be liaising with key stakeholders to determine ...
Posted by Michael Wonder on 28 Nov 2022
Joint statement: NICE and SMC/HIS collaboration
25 November 2022 - NICE and SMC/HIS collaboration on the health technology appraisal of tixagevimab–cilgavimab (Evusheld) for preventing COVID-19. ...
Posted by Michael Wonder on 12 Dec 2019
NICE and the SMC have published recommendations on Shionogi’s Mulpleo (lusutrombopag), approving its use for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
12 December 2019 - Mulpleo (lusutrombopag) is the first licensed treatment to be made available through the National Health Service ...
Posted by Michael Wonder on 21 Mar 2018
Using real world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies
21 March 2018 - This study examines whether real world data is incorporated in health technology assessment (HTA) of melanoma drugs ...